Cascadian Therapeutics (CASC) reported quarterly earnings results on Monday, Aug-8-2016. The company reported $-0.26 earnings per share for the quarter, missing the analyst consensus estimate by $-0.14. Analysts had a consensus of $-0.12. During the same quarter in the previous year, the company posted $-0.11 EPS.
In a different news, on Jun 28, 2016, Scott Dunseth Myers (CEO) purchased 62,500 shares at $0.80 per share price.